Heterologous immunity: Immunopathology, autoimmunity and protection during viral infections

Autoimmunity

Volumn 44, Issue 4, 2011, Pages 328-347

  Selin, Liisa K ^a   Wlodarczyk, Myriam F ^a   Kraft, Anke R ^a   Nie, Siwei ^a   Kenney, Laurie L ^a   Puzone, Roberto ^b   Celada, Franco ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

autoimmunity; Heterologous immunity; immune modeling; T cell cross reactivity; viruses

Indexed keywords

ETANERCEPT; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA DR3 ANTIGEN; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 5; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; AUTOIMMUNITY; BRONCHIOLITIS OBLITERANS; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLITIS; CROSS REACTION; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; DENGUE VIRUS; EOSINOPHILIA; EPSTEIN BARR VIRUS; HEMORRHAGIC SHOCK; HEPATITIS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HETEROLOGOUS IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNITY; IMMUNOPATHOLOGY; IMMUNOPRECIPITATION; INFECTIOUS MONONUCLEOSIS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H2N2; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; LYMPHOID TISSUE; MEMORY T LYMPHOCYTE; NONHUMAN; PANNICULITIS; PICHINDE ARENAVIRUS; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; VACCINIA VIRUS; VIRUS INFECTION; WART VIRUS;

ANIMALS; AUTOIMMUNITY; HUMANS; IMMUNITY; VIRUS DISEASES; VIRUSES;

EID: 79954460462     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2011.523277     Document Type: Article

References (172)

1. Posnett DN. Herpesviruses and autoimmunity. Curr Opin Investig Drugs 2008;9(5):505-514. (Pubitemid 351677905)
2. Sips GJ, Chesik D, Glazenburg L, Wilschut J, De KJ, WilczakN. Involvement of morbilliviruses in the pathogenesis of demyelinating disease. Rev Med Virol 2007;17(4): 223-244. (Pubitemid 47066636)
3. Libbey JE, McCoy LL, Fujinami RS. Molecular mimicry in multiple sclerosis. Int Rev Neurobiol 2007;79:127-147.
4. Welsh RM, Fujinami RS. Pathogenic epitopes, heterologous immunity and vaccine design. Nat Rev Microbiol 2007;5(7): 555-563. (Pubitemid 46925383)
5. Sotelo J, Martinez-Palomo A, Ordonez G, Pineda B. Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis. Ann Neurol 2008;63(3):303-311. (Pubitemid 351506349)
6. Giraudon P, Bernard A. Chronic viral infections of the central nervous system: Aspects specific to multiple sclerosis. Rev Neurol (Paris) 2009;165(10):789-795.
7. Requena L, Requena C. Erythema nodosum. Dermatol Online 2002;8:4.
8. Smoller BR, Weishar M, Gray MH. An unusual cutaneous manifestation in Crohn's disease. Arch Pathol Lab Med 1990; 6:609-610. (Pubitemid 20180976)
9. Schlesinger C, Meyer CA, Veeraraghavan S, Koss MN. Constrictive (obliterative) bronchiolitis: Diagnosis, etiology, and a critical review of the literature. Ann Diagn Pathol 1998; 2:321-334. (Pubitemid 128646573)
10. Jones JF, Ray CG, Minnich LL, Hicks MJ, Kibler R, Lucas DO. Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: Elevated antiearly antigen antibodies. Ann Intern Med 1985;102:1-7. (Pubitemid 15187648)
11. Ho-Yen DO, McNamara I. The epidemiology of post viral fatigue syndrome. Scott Med J 1988;33:368-369. (Pubitemid 19029032)
12. Evans AC. Brucellosis in the United States. Am J Public Health 1947;37:139-151.
13. Truss CO. The role of Candida albicans in human illness. J Orthomol Psych 1981;10:228-238. (Pubitemid 12172597)
14. Daugherty SA, Henry BE, Peterson DL, Swarts RL, Bastien S, Thomas RS. Chronic fatigue syndrome in northern Nevada. Rev Infect Dis 1991;13(suppl 1): S39-S44.
15. Buchwald D, Cheney PR, Peterson DL, Henry B, Wormsley SB, Geiger A, Ablashi DV, Salahuddin SZ, Saxinger C, Biddle R, Kikinis R, Jolesz FA, Folks T, Balachandran N, Peter JB, Gallo RC, Komaroff AL. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active herpesvirus type 6 infection. Ann Intern Med 1992;116:103-113.
16. Chia JK, Chia AY. Chronic fatigue syndrome is associated with chronic enterovirus infection of the stomach. J Clin Pathol 2008;61(1):43-48. (Pubitemid 351158224)
17. Chia JK. The role of enterovirus in chronic fatigue syndrome. J Clin Pathol 2005;58(11):1126-1132. (Pubitemid 41566453)
18. Lombardi VC, Ruscetti FW, Das GJ, Pfost MA, Hagen KS, Peterson DL, Ruscetti SK, Bagni RK, Petrow-Sadowski C, Gold B, Dean M, Silverman RH, Mikovits JA. Detection of an infectious retrovirus,XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009;326(5952): 585-589.
19. Jones JF. Serologic and immunologic responses in chronic fatigue syndrome with emphasis on the Epstein-Barr virus. Rev Infect Dis 1991;13(suppl 1):S26-S31.
20. Selin LK, Nahill SR, Welsh RM. Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses. J Exp Med 1994;179:1933-1943. (Pubitemid 24155674)
21. Brehm MA, Pinto AK, Daniels KA, Schneck JP, Welsh RM, Selin LK. T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat Immunol 2002;3(7):627-634. (Pubitemid 34752471)
22. Selin LK, Vergilis K, Welsh RM, Nahill SR. Reduction of otherwise remarkably stable virus-specific cytotoxic T lymphocyte memory by heterologous viral infections. J Exp Med 1996;183:2489-2499. (Pubitemid 26192358)
23. Selin LK, Lin MY, Kraemer KA, Schneck JP, Pardoll D, Varga SM, Santolucito PA, Pinto AK,Welsh RM. Attrition of T cell memory: Selective loss of lymphocytic choriomeningitis virus (LCMV) epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity 1999;11:733-742. (Pubitemid 30030712)
24. Selin LK, Varga SM, Wong IC, Welsh RM. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J Exp Med 1998;188:1705-1715. (Pubitemid 28516115)
25. Welsh RM, Selin LK. No one is naïve: The significance of heterologous T-cell immunity. Nat Rev Immunol 2002;2(6): 417-426. (Pubitemid 37328749)
26. Rock KL, York IA, Saric T, Goldberg AL. Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol 1903;80:1-70, JID 0370425.
27. Doherty PC, Zinkernagel RM. T-cell-mediated immunopathology in viral infections. Transplant Rev 1974;19: 89-120.
28. + T cells. Proc Natl Acad Sci USA 2001;98:6313-6318. (Pubitemid 32488236)
29. Kaech SM, Ahmed R. Memory CD8s T cell differentiation: Initial antigen encounter triggers a developmental program in naïve cells. Nat Immunol 2001;2:415-422. (Pubitemid 33706139)
30. Mercado R, Vijh S, Allen SE, Kerksiek K, Pilip IM, Pamer EG. Early programming of T cell populations responding to bacterial infection. J Immunol 2000;165: 6833-6839. (Pubitemid 32001151)
31. van Stipdonk MJ, Lemmens EE, Schoenberger SP. Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2001;2: 423-429. (Pubitemid 33706140)
32. + CTL response. J Exp Med 1996;183:2129-2142. (Pubitemid 26158905)
33. + memory T cells. Nature 2006;441(7095):890-893.
34. York IA, Brehm MA, Zendzian S, Towne CF, Rock KL. Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance. Proc Natl Acad Sci USA 2006;103(24):9202-9207. (Pubitemid 43902556)
35. Razvi ES,Welsh RM,McFarland HI. In vivo state of antiviral CTL precursors: Characterization of a cycling population containing CTL precursors in immune mice. J Immunol 1995;154:620-632.
36. Selin LK, Welsh RM. Cytolytically active memory CTL present in lymphocytic choriomeningitis virus (LCMV)- immune mice after clearance of virus infection. J Immunol 1997;158:5366-5373. (Pubitemid 127681243)
37. + memory T cells in virus-infected hosts. J Exp Med 1996;183:1367-1375. (Pubitemid 26134280)
38. McNally JM, Zarozinski CC, LinMY, Brehm MA, ChenHD, Welsh RM. Attrition of bystander CD8 T cells during virusinduced T cell and interferon responses. J Virol 2001;75: 5965-5976. (Pubitemid 32553127)
39. Tumpey TM, Lu X, Morken T, Zaki SR, Katz JM. Depletion of lymphocytes and diminished cytokine production in mice infected with a highly virulent influenza A (H5N1) virus isolated from humans. J Virol 2000;74(13):6105-6116, JID 0113724. (Pubitemid 30412982)
40. Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 2000; 80(2):171-186, JID 0376617. (Pubitemid 30120970)
41. Dietz WHJ, Peralta PH, Johnson KM. Ten clinical cases ofhuman infection with venezuelan equine encephalomyelitisvirus, subtype I-D. Am J Trop Med Hyg 1979;28(2): 329-334, JID 0370507. (Pubitemid 9155842)
42. Bahl K, Kim SK, Calcagno C, GhersiD, Puzone R, Celada F, Selin LK, Welsh RM. IFN-induced attrition of CD8 T cells in the presence or absence of cognate antigen during the early stages of viral infections. J Immunol 2006;176(7): 4284-4295. (Pubitemid 44264408)
43. Jiang J, Gross D, Nogusa S, Elbaum P, Murasko DM. Depletion of T cells by type I interferon: Differences between young and aged mice. J Immunol 2005;175(3):1820-1826. (Pubitemid 41023087)
44. Jiang J, Lau LL, Shen H. Selective depletion of nonspecific T cells during the early stage of immune responses to infection. J Immunol 2003;171(8):4352-4358. (Pubitemid 37238713)
45. Selin LK, Cornberg M, Brehm MA, Kim SK, Calcagno C, Ghersi D, Puzone R, Celada F, Welsh RM. CD8 memory T cells: Cross-reactivity and heterologous immunity. Semin Immunol 2004;16(5):335-347. (Pubitemid 39446560)
46. Selin LK,Welsh RM. Plasticity of T cell memory responses to viruses. Immunity 2004;20(1):5-16. (Pubitemid 38134289)
47. Kim SK,Welsh RM. Comprehensive early and lasting loss of memory CD8 T cells and functional memory during acute and persistent viral infections. J Immunol 2004;172(5): 3139-3150. (Pubitemid 38263704)
48. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999;17:51-88. (Pubitemid 29241119)
49. + T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. J Clin Invest 2005;115(12): 3602-3612. (Pubitemid 43121849)
50. Mason D. A very high level of crossreactivity is an essential feature of the T cell repertoire. Immunol Today 1998;19: 395-404. (Pubitemid 28392279)
51. Wilson DB, Wilson DH, Schroder K, Pinilla C, Blondelle S, Houghten RA, Garcia KC. Specificity and degeneracy of T cells. Mol Immunol 2004;40(14-15):1047-1055. (Pubitemid 38221185)
52. Selin LK, Brehm MA. Frontiers in nephrology: Heterologous immunity, T cell cross-reactivity, and alloreactivity. J Am Soc Nephrol 2007;18(8):2268- 2277. (Pubitemid 47203841)
53. Welsh RM, Che JW, Brehm MA, Selin LK. Heterologous immunity between viruses. Immunol Rev 2010;235(1): 244-266.
54. Welsh RM, Selin LK, Szomolanyi-Tsuda E. Immunological memory to viral infections. Annu Rev Immunol 2004;22: 711-743. (Pubitemid 38680439)
55. Acierno PM, Newton DA, Brown EA, Maes LA, Baatz JE, Gattoni-Celli S. Cross-reactivity between HLA-A2-restricted FLU-M1:58-66 and HIV p17 GAG:77-85 epitopes in HIV-infected and uninfected individuals. J Transl Med 2003;1:3-7.
56. + T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein. J Virol 2003; 77(9):5464-5474. (Pubitemid 36460959)
57. Frankild S, De Boer RJ, Lund O, Nielsen M, Kesmir C. Amino acid similarity accounts for T cell cross-reactivity and for 'holes' in the T cell repertoire. PLoS ONE 2008;3(3): e1831.
58. Bahl K, Huebner A, Davis RJ, Welsh RM. Analysis of apoptosis of memory T cells and dendritic cells during the early stages of viral infection or exposure to toll-like receptor agonists. J Virol 2010;84(10):4866-4877.
59. van der Most RG, Sette A, Oseroff C, Alexander J, Murali- Krishna K, Lau LL, Southwood S, Sidney J, Chesnut RW, Matloubian M, Ahmed R. Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J Immunol 1996;157(12):5543-5554. (Pubitemid 126448976)
60. Whitton JL, Southern PJ, Oldstone MBA. Analyses of the cytotoxic T lymphocyte responses to glycoprotein and nucleoprotein components of lymphocytic choriomeningitis virus. Virol 1988;162:321-327. (Pubitemid 18068917)
61. Chen W, Anton LC, Bennink JR, Yewdell JW. Dissecting the multifactorial causes of immunodominace in class I-restricted T cell responses to viruses. Immunity 2000;12:83-93. (Pubitemid 30069217)
62. Vitiello A, Yuan L, Chesnut RW, Sidney J, Southwood S, Farness P, Jackson MR, Peterson PA, Sette A. Immunodominance analysis of CTL responses to influenza PR8 virus reveals two dominant and subdominant Kb-restricted epitopes. J Immunol 1996;157:5555-5562. (Pubitemid 126448977)
63. Maryanski JL, Attuil V, Hamrouni A, Mutin M, Rossi M, Aublin A, Bucher P. Individuality of Ag-selected and preimmune TCR repertoires. Immunol Res 2001;23(1): 75-84. (Pubitemid 32493720)
64. Lin MY, Welsh RM. Stability and diversity of T cell receptor (TCR) repertoire usage during lymphocytic choriomeningitis virus infection of mice. J Exp Med 1998;188:1993-2005. (Pubitemid 28562517)
65. Blattman JN, Sourdive DJ, Murali-Krishna K, Ahmed R, Altman JD. Evolution of the T cell repertoire during primary, memory, and recall responses to viral infection. J Immunol 2000;165:6081-6090.
66. + T cell populations. Nat Immunol 2005;6(4):382-389. (Pubitemid 41716778)
67. Cornberg M, Chen AT, Wilkinson LA, Brehm MA, Kim SK, Calcagno C, Ghersi D, Puzone R, Celada F, Welsh RM, Selin LK. Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J Clin Invest 2006; 116(5):1443-1456.
68. Kim SK, Cornberg M, Wang XZ, Chen HD, Selin LK, Welsh RM. Private specificities of CD8 T cell responses control patterns of heterologous immunity. J Exp Med 2005; 201(4):523-533. (Pubitemid 40289543)
69. Nie S, Lin SJ, Kim SK, Welsh RM, Selin LK. Pathological features of heterologous immunity are regulated by the private specificities of the immune repertoire. Am J Pathol 2010;176(5):2107-2112.
70. Urbani S, Amadei B, Fisicaro P, Pilli M, Missale G, Bertoletti A, Ferrari C. Heterologous T cell immunity in severe hepatitis C virus infection. J Exp Med 2005;201: 675-680. (Pubitemid 40395112)
71. Mongkolsapaya J, DejnirattisaiW, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, Sawasdivorn S, Duangchinda T, Dong T, Rowland-Jones S, Yenchitsomanus PT, McMichael A, Malasit P, Screaton G. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003;9(7):921-927. (Pubitemid 36889936)
72. Kasprowicz V, Ward SM, Turner A, Grammatikos A, Nolan BE, Lewis-Ximines L, Sharp C, Woodfruff J, Fleming VM, Sims S, Walker BD, Sewell AK, Lauer GM, Klenerman P. Defining the directionality and quality of influenza virus-specific CD8 T cell cross-reactivity in individuals infected with hepatitis C virus. J Clin Invest 2008;118(3):1143-1153. (Pubitemid 351364621)
73. Page KR, Scott AL, Manabe YC. The expanding realm of heterologous immunity: Friend or foe? Cell Microbiol 2006; 8(2):185-196. (Pubitemid 43356042)
74. Chen HD, Fraire AE, Joris I, Welsh RM, Selin LK. Specific history of heterologous virus infections determines anti-viral immunity and immunopathology in the lung. Am J Pathol 2003;163(4):1341-1355. (Pubitemid 37175083)
75. Cornberg M, Clute SC,Watkin LB, Saccoccio FM, Kim SK, Naumov YN, Brehm MA, Aslan N, Welsh RM, Selin LK. CD8 T cell cross-reactivity networks mediate heterologous immunity in human EBV and murine vaccinia virus infections. J Immunol 2010;184(6):2825-2838.
76. + T cells in heterologous antiviral immunity and immunopathology in the lung. Nat Immunol 2001;2:1067-1076. (Pubitemid 33069503)
77. Nie S, Cornberg M, Selin LK. Resistance to vaccinia virus is less dependent on TNF under conditions of heterologous immunity. J Immunol 2009;183(10):6554-6560.
78. Kim SK, Brehm MA, Welsh RM, Selin LK. Dynamics of memory T cell proliferation under conditions of heterologous immunity and bystander stimulation. J Immunol 2002; 169(1):90-98. (Pubitemid 34686124)
79. Brehm MA, Pinto AK, Daniels KA, Schneck JP, Welsh RM, Selin LK. T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat Immunol 2002;3:627-634. (Pubitemid 34752471)
80. Cornberg M, Sheridan BS, Saccoccio FM, Brehm MA, Selin LK. Protection against vaccinia virus challenge by CD8 memory T cells resolved by molecular mimicry. J Virol 2007; 81(2):934-944. (Pubitemid 46067918)
81. Cole GA, Nathanson N, Prendergast RA. Requirement for q-bearing cells in lymphocytic choriomeningitis virus-induced central nervous system disease. Nature 1972; 238:335-337.
82. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiological study of altered clinical reactivity to respiratory syncitial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969;89:405-421.
83. Cannon MJ, Openshaw PJM, Askonas BA. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 1988;168:1163-1168.
84. Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 1991;88:1026-1033.
85. + cytotoxic T cells to virus clearance or pathologic manifestations of influenza virus infection in a T cell receptor transgenic mouse model. J Exp Med 1998;188:223-232. (Pubitemid 28357751)
86. Sloan-Lancaster J, Allen PM. Altered peptide ligand-induced partial T cell activation: Molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996;14:1-27. (Pubitemid 26130175)
87. Kersh GJ, Kersh EN, Fremont DH, Allen PM. High- and low-potency ligands with similar affinities for the TCR: The importance of kinetics in TCR signaling. Immunity 1998;9: 817-826. (Pubitemid 29024461)
88. Ding Y-H, Baker BM, Garboczi DN, Biddison WE, Wiley DC. Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Immunity 1999;11:45-56. (Pubitemid 29359956)
89. Hemmer B, Stefanova I, Vergelli M, Germain RN, Martin R. Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. J Immunol 1998;160:5807-5814. (Pubitemid 28298038)
90. Zehn D, Lee SY, Bevan MJ. Complete but curtailed T-cell response to very low-affinity antigen. Nature 2009; 458(7235):211-214.
91. Guy CS, Vignali DA. Organization of proximal signal initiation at the TCR:CD3 complex. Immunol Rev 2009; 232(1):7-21.
92. Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B. Cross-reactivity between hepatitis C virus and influenza A virus determinant-specific cytotoxic T cells. J Virol 2001;75:11392-11400. (Pubitemid 33063230)
93. Rehermann B, Shin EC. Private aspects of heterologous immunity. J Exp Med 2005;201(5):667-670. (Pubitemid 40395110)
94. Zivny J, DeFronzo M, Jarry W, Jameson J, Cruz J, Ennis FA, Rothman AL. Partial agonist effect influences the CTL response to a heterologous dengue virus serotype. J Immunol 1999;163(5):2754-2760. (Pubitemid 29399202)
95. Yang H, Joris I, Majno G, Welsh RM. Necrosis of adipose tissue induced by sequential infections with unrelated viruses. Am J Pathol 1985;120:173-177. (Pubitemid 16255948)
96. Yang H, Dundon PL, Nahill SR, Welsh RM. Virus-induced polyclonal cytotoxic T lymphocyte stimulation. J Immunol 1989;142:1710-1718. (Pubitemid 19086343)
97. + T-cell epitopes in the murine intranasal challenge model. Eur J Immunol 2009;39(3):717-722.
98. Mathurin KS, Martens GW, Kornfeld H, Welsh RM. CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses. J Virol 2009;83(8):3528-3539.
99. Ploegh HL. Viral strategies of immune evasion. Science 1998; 280:248-253. (Pubitemid 28178062)
100. Xiao Z, Casey KA, Jameson SC, Curtsinger JM, Mescher MF. Programming for CD8 T cell memory development requires IL-12 or type I IFN. J Immunol 2009;182(5):2786-2794.
101. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 2005;202(5): 637-650. (Pubitemid 41248415)
102. + T lymphocytes during experimental mycobacterial infection. Infect Immun 2004;72(12):6884-6891. (Pubitemid 39552355)
103. + T cells provide innate immune protection against Listeria monocytogenes in the absence of cognate antigen. J Exp Med 2003;198(10):1583-1593. (Pubitemid 37467172)
104. + memory T cells are preferential targets for bystander activation and apoptosis. J Immunol 2009;182(4):1962-1971.
105. +-Tcell expansion and heterologous immunity. Infect Immun 2005;73(12):7996-8001. (Pubitemid 41740285)
106. + T cells by lipopolysaccharide-induced IL-12 and IL-18. J Immunol 2004;173(11):6873-6881. (Pubitemid 39541074)
107. Bukowski JF, Welsh RM. Enhanced susceptibility to cytotoxic T lymphocytes of target cells isolated from virusinfected or interferon-treated mice. J Virol 1986;59: 735-739. (Pubitemid 16011138)
108. Bukowski JF, Welsh RM. Interferon enhances the susceptibility of virus-infected fibroblasts to cytotoxic T cells. J Exp Med 1985;161:257-262. (Pubitemid 15169734)
109. + T cells during primary and secondary viral infections. J Immunol 2005;174(10): 5936-5940. (Pubitemid 40663779)
110. Haanen JB, Wolkers MC, Kruisbeek AM, Schumacher TN. Selective expansion of cross-reactive CD8() memory T cells by viral variants. J Exp Med 1999;190(9):1319-1328. (Pubitemid 29522215)
111. Nettesheim P, Szakal AK. Morphogenesis of alveolar bronchiolization. Lab Invest 1972;26:210-219.
112. Wlodarczyk MF, Kraft AR, ChenHD, Kenney LL, Selin LK. Pathological consequences of heterologous immunity pre-vented by inhibition of cross-reactive influenza A specific memory CD8 T-cells, 2010; submitted for publication.
113. + T cells. Immunity 2001;15: 637-646. (Pubitemid 33016448)
114. Johnson TR, Graham BS. Secreted respiratory syncytial virus G glcoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-dependent mechanism. J Virol 1999; 73:8485-8495. (Pubitemid 29441712)
115. Walzl G, Tafuro S, Moss P, Openshaw PJ, Hussell T. Influenza virus lung infection protects from respiratory syncitial virus-induced immunopathology. J Exp Med 2000; 192:1317-1326.
116. Aaby P, Samb B, Simondon F, Seck AM, Knudsen K, Whittle H. Non-specific beneficial effect of measles immunisation: Analysis of mortality studies from developing countries. Br Med J 1995;311:481-485.
117. Flanagan KL, Klein S, Skakkebaek NE, Marriott I, Marcha A, Selin LK, Fish E, Prentice A, Whittle H, Benn C, Aaby P. On behalf of the optimize immunization network (optimmunize). Sex-specific and non-specific effects of vaccines: Do they exist and what should be done?, 2010; submitted for publication
118. Stensballe LG, Nante E, Jensen IP, Kofoed PE, Poulsen A, Jensen H, Newport M, Marchant A, Aaby P. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: A beneficial effect of BCG vaccination for girls community based case-control study. Vaccine 2005;23(10):1251-1257. (Pubitemid 40126528)
119. Farrington CP, Firth MJ, Moulton LH, Ravn H, Andersen PK, Evans S. Epidemiological studies of the non-specific effects of vaccines: II-methodological issues in the design and analysis of cohort studies. Trop Med Int Health 2009;14(9):977-985.
120. Benn CS, Rodrigues A,Yazdanbakhsh M, Fisker AB, Ravn H, Whittle H, Aaby P. The effect of high-dose vitamin A supplementation administered with BCG vaccine at birth may be modified by subsequent DTP vaccination. Vaccine 2009;27(21):2891-2898.
121. Aaby P, Biai S, Veirum JE, Sodemann M, Lisse I, Garly ML, Ravn H, Benn CS, Rodrigues A. DTP with or after measles vaccination is associated with increased in-hospital mortality in Guinea-Bissau. Vaccine 2007;25(7):1265-1269. (Pubitemid 46039847)
122. Jennes W, Verheyden S, Demanet C, Adje-Toure CA, Vuylsteke B, Nkengasong JN, Kestens L. Cutting edge: Resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J Immunol 2006;177(10):658-692.
123. Tillmann HL, Heiken H, Knapik-Botor A, Heringlake S, Ockenga J, Wilber JC, Goergen B, Detmer J, McMorrow M, Stoll M, Schmidt RE, Manns MP. Infection with GB virus C and reduced mortality among HIV-infected patients.NEngl J Med 2001;345:715-724.
124. Clute SC, Naumov YN, Watkin LB, Aslan N, Sullivan JL, Luzuriaga K, Welsh RM, Puzone R, Celada F, Selin LK. Broad cross-reactive T cell receptor repertoires recognizing dissimilar Epstein-Barr and influenza A virus epitopes. J Immunol 2010.
125. Borja-Hart NL, Benavides S, Christensen C. Human papillomavirus vaccine safety in pediatric patients: An evaluation of the vaccine adverse event reporting system. Ann Pharmacother 2009;43(2):356-359.
126. Debeer P, De MP, Bruyninckx F, Devlieger R. Brachial plexus neuritis following HPV vaccination. Vaccine 2008; 26(35):4417-4419.
127. Debold V, Hurwitz E. Adverse events and quadrivalent human papillomavirus recombinant vaccine. J Am Med Assoc 2009;302(24):2657-2658.
128. Ojaimi S, Buttery JP, Korman TM. Quadrivalent human papillomavirus recombinant vaccine associated lipoatrophy. Vaccine 2009;27(36):4876-4878.
129. Khalifa YM, Monahan PM, Acharya NR. Ampiginous choroiditis following quadrivalent human papilloma virus vaccine. Br J Ophthalmol 2010;94(1):137-139.
130. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. J Am Med Assoc 2009;302(7):750-757.
131. Effros RB, Doherty PC, Gerhard W, Bennink J. Generation of both cross-reactive and virus-specific T-cell populations after immunization with serologically distinct influenza A viruses. J Exp Med 1977;145(3):557-568. (Pubitemid 8049609)
132. Lee LY, Ha do LA, Simmons C, de Jong MD, Chau NV, Schumacher R, Peng YC, McMichael AJ, Farrar JJ, Smith GL, Townsend AR, Askonas BA, Rowland-Jones S, Dong T. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 2008;118(10): 3478-3490.
133. Epstein SL. Prior H1N1 influenza infection and susceptibility of Cleveland family study participants during the H2N2 pandemic of 1957: An experiment of nature. J Infect Dis 2006;193(1):49-53. (Pubitemid 43032498)
134. Slepushkin AN. The effect of a previous attack of A1 influenza on susceptibility to A2 virus during the 1957 outbreak. Bull World Health Organ 1959;20(2-3):297-301.
135. Moss PAH, Moots RJ, Rosenberg WMC, Rowland-Jones SJ, Bodmer HC, McMichael AJ, Bell JI. Extensive conservation of a and b chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide. Proc Natl Acad Sci USA 1991;88:8987-8990.
136. Naumov YN, Naumova EN, Yassai MB, Kota K,Welsh RM, Selin LK. Multiple glycines in TCR alpha-chains determine clonally diverse nature of human T cell memory to influenza A virus. J Immunol 2008;181(10):7407-7419.
137. Weinstein L, Meade RH. Respiratory manifestations of chickenpox. Arch Intern Med 1956;98:91-99.
138. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, Chanock RM,Melnick JL, Monath TP, Roizman B, Straus SS, editors. Virology., Vol. 2 Philadelphia, PA: Lippincott-Raven Publishers; 1996. p 2397-2446.
139. Silins SL, Sherritt MA, Silleri JM, Cross SM, Elliott SL, Bharadwaj M, Le TT, Morrison LE, Khanna R, Moss DJ, Suhrbier A, Misko IS. Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood 2001;98(13):3739-3744.
140. Morens DM. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 1994; 19(3):500-512. (Pubitemid 24286955)
141. Halstead SB. Antibody, macrophages, dengue virus infection, shock and hemorrhage: A pathogenetic cascade. Rev Infect Dis 1989;11:S830-S839.
142. Matthew A, Kurane I, Green S, Stephens HAF, Vaughn DW, Kalayanarooj S, Suntayakorn S, Chandanayingyong D, Ennis FA, Rothman AL. Predominance of HLA-restricted cytotoxic T-lymphocyte responses to serotype-cross-reactive epitopes on nonstructural proteins following natural secondary dengue virus infection. J Virol 1998;72:3999-4004. (Pubitemid 28188703)
143. Suri-Payer E, Fritzsching B. Regulatory T cells in experimental autoimmune disease. Springer Semin Immunopathol 2006;28(1):3-16. (Pubitemid 44267954)
144. + natural regulatory T cells in dominantself-tolerance and autoimmune disease. Immunol Rev 2006; 212:8-27. (Pubitemid 44116697)
145. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008;133(5):775-787. (Pubitemid 351707693)
146. Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol 2009;27: 313-338.
147. + regulatory T cells. J Immunol 2003;170(8): 3939-3943. (Pubitemid 36428153)
148. + cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum 2003;48(5):1452-1460. (Pubitemid 36554546)
149. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(φ)CD25() T-cells from patients with type 1 diabetes. Diabetes 2005; 54(1):92-99. (Pubitemid 40105099)
150. Mittrucker HW, Kaufmann SH. Mini-review. Regulatory T cells and infection: Suppression revisited. Eur J Immunol 2004;34(2):306-312. (Pubitemid 39255940)
151. Rouse BT, Sarangi PP, Suvas S. Regulatory T cells in virus infections. Immunol Rev 2006;212:272-286. (Pubitemid 44116714)
152. Belkaid Y, Tarbell K. Regulatory T cells in the control of host-microorganism interactions (*). Annu Rev Immunol 2009;27:551-589.
153. Zelinskyy G, Dietze KK, Husecken YP, Schimmer S, Nair S, Werner T, Gibbert K, KershawO, Gruber AD, Sparwasser T, Dittmer U. The regulatory T-cell response during acute retroviral infection is locally defined and controls the magnitude and duration of the virus-specific cytotoxic T-cell response. Blood 2009;114(15):3199-3207.
154. + regulatory T cell responses during Friend retrovirus infection. Eur J Immunol 2006;36(10):2658-2670. (Pubitemid 44608450)
155. + T cell responses. J Exp Med 2003;198(6):889-901. (Pubitemid 37152926)
156. + regulatory T cells control the severity of viral immunoinflammatory lesions. J Immunol 2004;172(7): 4123-4132. (Pubitemid 38375224)
157. Zhao Z-S, Granucci F, Yeh L, Schaffer PA, Cantor H. Molecular mimicry by herpes simplex virus-type 1: Autoimmune disease after viral infection. Science 1998;279: 1344-1347. (Pubitemid 28119574)
158. Hiemstra HS, Schloot NC, van Veelen PA, Willemen SJ, Franken KL, van Rood JJ, de Vries RR, Chaudhuri A, Behan PO, Drijfhout JW, Roep BO. Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase. Proc Natl Acad Sci USA 2001;98(7):3988-3991. (Pubitemid 32249885)
159. Oldstone MB, Nerenberg M, Southern P, Price J, Lewicki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: Role of anti-self (virus) immune response. Cell 1991;65(2):319-331. (Pubitemid 121006061)
160. Evans CF, Horwitz MS, Hobbs MV, Oldstone MBA. Viral infection of transgenic mice expressing a viral protein in oligodendrocytes leads to chronic central nervous system autoimmune disease. J Exp Med 1996;184:2371-2384. (Pubitemid 27023736)
161. Kagi D, Odermatt B, Ohashi PS, Zinkernagel RM, Hengartner H. Development of insulitis without diabetes in transgenic mice lacking perforin-dependent cytotoxicity. J Exp Med 1996;183(5):2143-2152. (Pubitemid 26158906)
162. ChristenU, Edelmann KH, McGavern DB,WolfeT, Coon B, Teague MK, Miller SD, Oldstone MB, von Herrath MG. A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes. J Clin Invest 2004;114: 1290-1298. (Pubitemid 40385300)
163. McCoy L, Tsunoda I, Fujinami RS. Multiple sclerosis and virus induced immune responses: Autoimmunity can be primed by molecular mimicry and augmented by bystander activation. Autoimmunity 2006;39(1):9-19. (Pubitemid 43878516)
164. Theil DJ, Tsunoda I, Rodriguez F, Whitton JL, Fujinami RS. Viruses can silently prime for and trigger central nervous system autoimmune disease. J Neurovirol 2001;7(3): 220-227. (Pubitemid 32685256)
165. Sospedra M, Zhao Y, zur HH, Muraro PA, Hamashin C, de Villiers EM, Pinilla C, Martin R. Recognition of conserved amino acid motifs of common viruses and its role in autoimmunity. PLoS Pathog 2005;1(4):e41.
166. Welsh RM, Rothman AL. Dengue immune response: Low affinity, high febrility. Nature Med 2003;9:820-822. (Pubitemid 36889915)
167. Barton ES, White DW, Cathelyn JS, Brett-McClellan KA, Engle M, Diamond MS, Miller VL, Virgin HW. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 2007;447(7142):326-329. (Pubitemid 46788830)
168. Di Giusto CA, Bernhard JD. Erythema nodosum provoked by hepatitis B vaccine. Lancet 1986;2(8514):1042. (Pubitemid 16005650)
169. Cheng C, Gall JG, Nason M, King CR, Koup RA, Roederer M, McElrath MJ, Morgan CA, Churchyard G, Baden LR, Duerr AC, Keefer MC, Graham BS, Nabel GJ. Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J Virol 2010;84(1):630-638.
170. DiMario FJ, Jr, Hajjar M, Ciesielski T. A 16-year-old girl with bilateral visual loss and left hemiparesis following an immunization against human papilloma virus. J Child Neurol 2010;25(3):321-327.
171. Williams OM, Hart KW, Wang EC, Gelder CM. Analysis of CD4(φ) T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types. J Virol 2002;76(15):7418-7429. (Pubitemid 34760964)
172. Ahmed R, Gray D. Immunological memory and protective immunity: Understanding their relation. Science 1996;272: 54-60. (Pubitemid 26110754)